Inomax (Nitric Oxide)

Nitric oxide delivered by Inomax diffuses into the lung vasculature and activates soluble guanylate cyclase. This raises cyclic GMP levels, which relaxes smooth‑muscle cells in the pulmonary arteries, producing targeted vasodilation without significant systemic effects.

The dose of Inomax is determined by the prescribing clinician based on the patient’s condition, response, and monitoring results. Dosage is individualized and adjusted according to pulmonary artery pressure, oxygenation, and safety parameters.

Safety data for Inomax in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Inomax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Inomax delivers nitric oxide directly to the lungs, offering rapid and selective pulmonary vasodilation, whereas systemic agents such as phosphodiesterase‑5 inhibitors affect the whole circulatory system. This selectivity reduces systemic hypotension but requires specialized delivery equipment and monitoring.

Inomax cylinders should be stored at ambient temperature, kept in their original packaging, and protected from heat and direct sunlight. Ensure the cylinder is secured upright and that any leak‑detection equipment is functional before use.

Inomax is administered via a calibrated delivery system that introduces the gas into the endotracheopulmonary circuit. The clinician sets the flow rate according to the prescribed dose, and continuous monitoring of oxygenation and methemoglobin levels is performed throughout therapy.

The most serious risks include severe methemoglobinemia, rebound pulmonary hypertension after abrupt discontinuation, and nitrogen dioxide‑induced lung injury. Prompt recognition and appropriate management, such as gradual weaning and methemoglobin monitoring, are essential to mitigate these risks.

Inomax should be avoided in patients with known hypersensitivity to nitric oxide, severe anemia, or those who cannot be adequately monitored for methemoglobin levels and pulmonary pressures. Contraindications are determined by the treating physician based on individual clinical assessment.